FindTrial
Sign In

Tislelizumab Nab paclitaxel

DRUG3 trials

Sponsors

Tianjin Medical University Second Hospital, Sun Yat-sen University

Conditions

Head and Neck Cancer Squamous Cell CarcinomaHigh-Risk Non-Muscle Invasive Bladder Urothelial CarcinomaMuscle Invasive Bladder Cancer Urothelial CarcinomaNeoadjuvant ChemoimmunotherapyObjective Response RateSkull Base--Cancer

Phase 2

Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study
NCT05328336
Tianjin Medical University Second HospitalMuscle Invasive Bladder Cancer Urothelial Carcinoma
Start: 2021-11-11End: 2025-11-30Target: 74Updated: 2022-06-13
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study
NCT05418309
Tianjin Medical University Second HospitalHigh-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Start: 2021-12-27End: 2024-07-31Target: 63Updated: 2022-06-14
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
Not yet recruitingNCT07145931
Sun Yat-sen UniversityHead and Neck Cancer Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Objective Response Rate +1
Start: 2025-09-20End: 2029-09-20Target: 24Updated: 2025-08-28

Related Papers

TRUCE-11: An open-label, single-arm, multicenter phase II study of tislelizumab combined with nab-paclitaxel for muscle-invasive urothelial bladder carcinoma.
Journal of Clinical Oncology2026-05-27